| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $6.1M | — | -43.3% |
| SG&A Expense | $2.7M | — | -9.8% |
| Operating Income | -$8.8M | — | +36.0% |
| Net Income | -$4.6M | — | +46.1% |
| EPS (Basic) | -$0.05 | — | +64.3% |
| EPS (Diluted) | -$0.05 | — | +64.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $31.1M | -15.4% | +89.5% |
| Current Assets | $35.8M | -25.4% | +56.6% |
| Total Assets | $36.1M | -25.3% | +53.8% |
| Current Liabilities | $6.1M | -56.5% | -44.7% |
| Total Liabilities | $6.2M | -55.9% | -44.5% |
| Stockholders' Equity | $29.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.5M | — | +43.9% |
| Financing Cash Flow | -$233K | — | -118.0% |
| +143.8% |